Research programme: cannabinoid-based therapeutics - Revive Therapeutics

Drug Profile

Research programme: cannabinoid-based therapeutics - Revive Therapeutics

Alternative Names: REV 100; REV 101; REV 200; REV 201

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revive Therapeutics
  • Developer Revive Therapeutics; University of Wisconsin-Madison
  • Class Analgesics; Anti-inflammatories; Cannabinoids; Hepatoprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Skin disorders
  • Research Kidney disorders; Liver disorders; Neuropathic pain

Most Recent Events

  • 18 Dec 2017 Revive Therapeutics enters into collaboration agreement with Chemi Pharmaceuticals for cannabinoid-based therapeutics
  • 11 Oct 2017 Preclinical trials in Skin disorders in Canada (Topical)
  • 11 Oct 2017 Preclinical pharmacodynamics data in inflammatory Skin disorders released by Revive Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top